<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0606222137
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRAN 0.5 g powder for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEROPENEM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS DOBFAR S.P.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS DOBFAR S.P.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MIRAN</strong> contains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.</p><p><strong>MIRAN</strong> is used to treat the following in adults and children aged 3 months and older:</p><p>-&nbsp; Infection affecting the lungs (pneumonia).</p><p>-&nbsp; Lung and bronchial infections in patients suffering from cystic fibrosis.</p><p>-&nbsp; Complicated urinary tract infections.</p><p>-&nbsp; Complicated infections in the abdomen.</p><p>-&nbsp; Infections that you can catch during or after the delivery.</p><p>-&nbsp; Complicated skin and soft tissues infections.</p><p>-&nbsp; Acute bacterial infection of the brain (meningitis).</p><p><strong>MIRAN</strong> may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p><strong>MIRAN</strong> may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use MIRAN</strong></p><p>-&nbsp; If you are allergic (hypersensitive) to meropenem or any of the other ingredients of <strong>MIRAN</strong> (listed in Section 6: Further information).</p><p>-&nbsp; If you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or carbapenems as you may also be allergic to meropenem.</p><p><strong>Warnings and Precautions</strong></p><p>Check with your doctor, pharmacist or nurse before using <strong>MIRAN</strong>:</p><p>-&nbsp; If you have health problems, such as liver or kidney problems.</p><p>-&nbsp; If you have had severe diarrhoea after taking other antibiotics.</p><p>You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you.</p><p>You may develop signs and symptoms of severe skin reactions (see section 4). If this happens talk to your doctor or nurse immediately so that they can treat the symptoms.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or nurse before using <strong>MIRAN</strong>.</p><p><strong>Other medicines and MIRAN</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because <strong>MIRAN</strong> can affect the way some medicines work and some medicines can have an effect on <strong>MIRAN</strong>.</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:</p><p>-&nbsp; Probenecid (used to treat gout).</p><p>-&nbsp; Valproic acid/sodium valproate/valpromide (used to treat epilepsy). <strong>MIRAN</strong> should not be used because it may decrease the effect of sodium valproate.</p><p>-&nbsp; Oral anti-coagulant agent (used to treat or prevent blood clots).</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide whether you should use <strong>MIRAN</strong>.</p><p>It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving meropenem. Small amounts of this medicine may pass into the breast milk.</p><p>Therefore, your doctor will decide whether you should use <strong>MIRAN</strong> while breast-feeding.<strong> </strong></p><p><strong>Driving and using machines</strong></p><p>No studies on the effect on the ability to drive and use machines have been performed.</p><p>Meropenem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines.</p><p>Meropenem may cause involuntary muscle movements which may cause the person&#39;s body to shake rapidly and uncontrollably (convulsions). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect.</p><p><strong>Important information about some of the ingredients of MIRAN</strong></p><p><strong>MIRAN contains sodium.</strong></p><p>-&nbsp; Sodium content of MIRAN 1gm is 90.2mg/vial.</p><p>-&nbsp; Sodium content of MIRAN 0.5gm is 45.1mg/vial.</p><p><strong>If you have a condition which requires you to monitor your sodium intake please inform your </strong><strong>doctor, pharmacist or</strong> <strong>nurse.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Use in Adults</u></strong></p><p>-&nbsp; The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.</p><p>-&nbsp; The dose for adults is usually between 0.5g and 2g. You will usually receive a dose every 8 hours. However you may receive a dose less often if your kidneys do not work very well.</p><p><strong><u>Use in Children and adolescents</u></strong></p><p>-&nbsp; The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10mg and 40mg of <strong>MIRAN</strong> for each kilogram that the child weighs. A dose is usually given every 8 hours.</p><p>Children who weigh over 50 kg will be given an adult dose.</p><p><strong><u>How to use MIRAN</u></strong></p><p>-&nbsp; <strong>MIRAN</strong> will be given to you as an injection or infusion into a large vein.</p><p>-&nbsp; Your doctor or nurse will normally give <strong>MIRAN</strong> to you.</p><p>-&nbsp; <strong>MIRAN</strong> injection should not be mixed with or added to solutions that contain other medicines (<em>see below</em><strong> </strong><em>Incompatibilities</em>).</p><p>-&nbsp; The injection may take about 5 minutes or between 15 and 30 minutes. Your doctor will tell you how to give <strong>MIRAN</strong>.</p><p>-&nbsp; You should normally have your injections at the same times each day.</p><p><strong>If you use more MIRAN than you should</strong></p><p>If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p><strong>If you forget to use MIRAN</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection.</p><p>Do not have a double dose (two injections at the same time) to make up for a forgotten dose.</p><p><strong>If you stop using MIRAN</strong></p><p>Do not stop having <strong>MIRAN</strong> until your doctor tells you to.</p><p><strong>If you have any further questions on the use of this medicine, ask your </strong><strong>doctor, pharmacist or</strong> <strong>nurse.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Severe allergic reactions </strong></p><p>If you have any of these signs and symptoms,<strong> tell your doctor or nurse straight away. </strong>You may need urgent medical treatment. The signs and symptoms may include a sudden onset of:</p><p>-&nbsp; Severe rash, itching or hives on the skin.</p><p>-&nbsp; Swelling of the face, lips, tongue or other parts of the body.</p><p>-&nbsp; Shortness of breath, wheezing or trouble breathing.</p><p>-&nbsp; Serious skin reactions which include</p><p>&bull;&nbsp; Serious hypersensitivity reactions involving fever, skin rash, and changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome.</p><p>&bull;&nbsp; Severe red scaly rash, skin bumps that contain pus, blisters or peeling of skin, which may be associated with a high fever and joint pains.</p><p>&bull;&nbsp; Severe skin rashes that can appear as reddish circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome) or a more severe form (toxic epidermal necrolysis).</p><p><strong>Damage to red blood cells (not known) </strong></p><p><strong>The signs include:</strong></p><p>-&nbsp; Being breathless when you do not expect it.</p><p>-&nbsp; Red or brown urine.</p><p>If you notice any of the above, <strong>see a doctor straight away. </strong></p><p><strong>Other possible side effects:</strong></p><p><strong>Common (may affect up to 1 in 10 people).</strong></p><p>-&nbsp; Abdominal (stomach) pain.</p><p>-&nbsp; Feeling sick (nausea).</p><p>-&nbsp; Being sick (vomiting).</p><p>-&nbsp; Diarrhoea.</p><p>-&nbsp; Headache.</p><p>-&nbsp; Skin rash, itchy skin.</p><p>-&nbsp; Pain and inflammation.</p><p>-&nbsp; Increased numbers of platelets in your blood (shown in a blood test).</p><p>-&nbsp; Changes in blood tests, including tests that show how well your liver is working.</p><p><strong>Uncommon (may affect up to 1 in 100 people).</strong></p><p>-&nbsp; Changes in your blood. These include reduced numbers of platelets (which may make you bruise more easily), increased numbers of some white blood cells, decreased numbers of other white cells and increased amounts of a substance called &lsquo;bilirubin&rsquo;. Your doctor may do blood tests from time to time.</p><p>-&nbsp; Changes in blood tests, including tests that show how well your kidney is working.</p><p>-&nbsp; A tingling feeling (pins and needles).</p><p>-&nbsp; Infections of the mouth or the vagina that are caused by a fungus (thrush).</p><p>-&nbsp; Inflammation of the bowel with diarrhoea.</p><p>-&nbsp; Sore veins where <strong>MIRAN</strong> is injected.</p><p>-&nbsp; Other changes in your blood. The symptoms include frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time.</p><p><strong>Rare (may affect up to 1 in 1000 people).</strong></p><p>-&nbsp; Fits (convulsions).</p><p>-&nbsp; Acute disorientation and confusion (delirium).</p><p><strong><u>To report any side effect(s):</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at </strong>+966-11-2038222<strong>, Exts: </strong>2317-2356-2340</p><p><strong>Reporting Hotline: </strong>19999</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p><p>&bull;&nbsp; <strong>Other</strong><strong> GCC States: Please contact the relevant competent authority.</strong></p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; &nbsp;Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp; Do not use <strong>MIRAN</strong> after the expiry date which is stated on the carton and on the vial label. The expiry date refers to the last day of that month.</p><p>-&nbsp; Do not use <strong>MIRAN</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>-&nbsp; <strong>Before reconstitution, Store below 30&deg;C.</strong></p><p><strong>Stability after reconstitution</strong>:</p><p><strong><u>Intravenous bolus injection administration</u></strong></p><p>A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25&deg;C or 12 hours under refrigerated conditions (2-8&deg;C).</p><p>From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.</p><p>If not used immediately in-use storage times and conditions are the responsibility of the user.</p><p><strong><u>Intravenous infusion administration</u></strong></p><p>A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20mg/ml.</p><p>Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25&deg;C or 24 hours under refrigerated conditions (2-8&deg;C).</p><p>From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.</p><p>If not used immediately in-use storage times and conditions are the responsibility of the user.</p><p>Reconstituted solution of the product in 5% dextrose solution should be used immediately.</p><p>The constituted solutions should not be frozen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>The active substance is meropenem.</strong></p><p>Each vial contains sterile meropenem trihydrate equivalent to 0.5gm or 1gm of meropenem.</p><p>The other ingredient is sterile sodium carbonate.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                MIRAN 0.5gm or MIRAN 1gm is available in pack sizes of 1 vial each.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
01/10/2020

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ميران على المادة الفعالة ميروبينيم وينتمي إلى مجموعة الأدوية المعروفة بالمضادات الحيوية من فئة كاربابينيم. والذي يعمل عن طريق قتل البكتيريا التي يمكن أن تسبب الإصابة بعدوى خطيرة.</p><p dir="RTL">يستخدم <strong>ميران</strong> لدى البالغين و الأطفال بعمر 3 أشهر أو أكثر لعلاج الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تصيب الرئتين (النيمونيا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة والشعب الهوائية لدى المرضى الذين يعانون من التليف الكيسي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية المصحوبة بمضاعفات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عدوى البطن المصحوبة بمضاعفات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي يمكن حدوثها أثناء أو بعد عملية الولادة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة المصحوبة بمضاعفات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية الدماغية الحادة (التهاب السحايا).&nbsp;</p><p dir="RTL">يمكن استخدام<strong> ميران</strong> في علاج المرضى الذين يعانون من نقص الكريات المتعادلة المصحوبة بحدوث حمى والتي يتوقع أن يكون حدوثها ناتج عن الإصابة بعدوى بكتيرية.</p><p dir="RTL">كما يمكن استخدام <strong>ميران</strong> في علاج حالات العدوى البكتيرية في الدم والتي قد تصاحب أي من حالات العدوى المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم استعمال ميران في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه ميروبينيم أو أي من المكونات الأخرى في <strong>ميران </strong>(المذكورة في البند رقم 6.معلومات إضافية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه أحد المضادات الحيوية الأخرى بالمثل المضادات الحيوية من مجموعة البنسيلين، مجموعة السيفالوسبورين أو مجموعة الكاربابينيم، حيث أنك قد تعاني أيضاً من الحساسية تجاه ميروبينيم.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قم باستشارة طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض قبل استعمال<strong> </strong><strong>ميران</strong>:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل صحية، بالمثل مشاكل في الكبد أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت سابقاً من حدوث إسهال شديد بعد تناولك لأحد المضادات الحيوية الأخرى.</p><p dir="RTL">قد يظهر في فحص الدم نتائج إيجابية لاختبار كومب والتي تشير إلى وجود أجسام مضادة في الدم تعمل على تكسر خلايا الدم الحمراء. سيوضح لك الطبيب ذلك إذا لزم الأمر.</p><p dir="RTL">كما قد تعاني من ظهور أعراض وعلامات لتفاعلات جلدية شديدة (انظر البند رقم 4). في حال تعرضك لحدوث ذلك يرجى منك التحدث مع طبيبك المعالج أو الممرض على الفور حتى يتمكنوا من علاج الأعراض.</p><p dir="RTL">إذا لم تكن متأكداً بأن ما تم ذكره أعلاه ينطبق عليك، استشر طبيبك المعالج أو الممرض قبل استخدام <strong>ميران</strong>.</p><p dir="RTL"><strong>استعمال الأدوية الأخرى بالتزامن مع ميران</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى. حيث أن <strong>ميران</strong> قد يؤثر على آلية عمل بعض الأدوية، كما أن هذه الأدوية قد تؤثر أيضاً على آلية عمل <strong>ميران</strong>.</p><p dir="RTL">يجب عليك أن تخبر طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض خصيصاً إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; بروبنيسيد (دواء يستخدم لعلاج داء النقرس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حمض الفالبرويك/ فالبروات الصوديوم/فالبروميد (تستخدم لعلاج الصرع) . يجب عدم استخدام <strong>ميران </strong>بالتزامن في نفس الوقت حيث أنه قد يقلل من فعالية فالبروات الصوديوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر الفموية (يستخدم لعلاج أو لمنع الجلطات الدموية).</p><p dir="RTL"><strong>الحمل والرضاعة</strong> <strong>الطبيعية</strong></p><p>&nbsp; &nbsp;&nbsp;&nbsp;يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على المشورة الطبية قبل استعمال هذا الدواء، &nbsp;إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك حاملاً أو تخططين لكي تصبحين حاملاً. يفضل تجنب استعمال ميروبينيم أثناء الحمل. سوف يقرر طبيبك المعالج ما إذا كنت بحاجة ملحة إلى استخدام <strong>ميران</strong>.</p><p>كما أنه من المهم أيضاً إخبار طبيبك المعالج في حال كنت ترضعين طفلك رضاعة طبيعية أو تنوين القيام بذلك قبل تلقيك العلاج باستخدام ميروبينيم. قد تفرز كميات ضئيلة من ميروبينيم في حليب الثدي. لذلك، سوف يقرر طبيبك المعالج ما إذا كنت بحاجة ملحة إلى استخدام <strong>ميران</strong> أثناء الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تجرى أية دراسات حول تأثير ميروبينيم على القيادة وتشغيل الآلات.</p><p dir="RTL">صاحب استخدام ميروبينيم حدوث صداع وشعور بالوخز في الجلد (الشعور بالخدر). قد تؤثر أي من هذه الأعراض على قدرتك على القيادة وتشغيل الآلات.</p><p dir="RTL">كما قد يتسبب ميروبينيم في حدوث حركات عضلية لاإرادية تتسبب في اهتزاز الجسم بسرعة دون القدرة على التحكم بها (تشنجات). عادة ما يصاحب ذلك فقدان الوعي. يجب عليك عدم القيادة أو استخدام أي آلات في حال تعرضك لهذا التأثير الجانبي.</p><p dir="RTL"><strong>معلومات هامة عن بعض محتويات</strong> <strong>ميران</strong></p><p dir="RTL"><strong>يحتوي ميران على الصوديوم. </strong></p><p dir="RTL">يبلغ محتوى الصوديوم في <strong>ميران</strong> 1 غرام 90.2 ملغم/ زجاجة.</p><p dir="RTL">يبلغ محتوى الصوديوم في <strong>ميران</strong> 0.5 غرام 45.1 ملغم/ زجاجة.</p><p dir="RTL"><strong>إذا كنت تعاني من حالة مرضية تتطلب ضبط مستوى الصوديوم لديك، فيرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض بذلك. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>الاستخدام لدى فئة البالغون</u></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يعتمد مقدار الجرعة المعطاة على نوع العدوى، مكانها في الجسم ومدى خطورة هذه العدوى. سوف يحدد طبيبك المعالج مقدار الجرعة التي تحتاجها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عادة ما يتراوح مقدار الجرعة للكبار ما بين 0.5 غرام و2 غرام تعطى كل 8 ساعات. إلا أنه في أغلب الأحيان قد يعطى لك جرعة أقل إذا كنت تعاني من خلل في وظائف الكلى.&nbsp;</p><p dir="RTL"><strong><u>الاستخدام </u></strong><strong><u>لدى </u></strong><strong><u>فئة الأطفال والمراهقين</u></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يتم تحديد مقدار الجرعة للأطفال بعمر أكبر من 3 أشهر وحتى عمر 12 سنة وذلك وفقاً لعمر الطفل ووزنه. &nbsp;يبلغ مقدار الجرعة الاعتيادية من <strong>ميران</strong> ما بين 10 ملغم و40 ملغم لكل كيلوغرام من وزن الجسم. والتي عادة ما تعطى كل 8 ساعات.</p><p dir="RTL">الأطفال الذين يزنون أكثر من 50 كيلوغرام سوف يتم إعطائهم نفس مقدار الجرعة التي تعطى لفئة البالغون.</p><p dir="RTL"><strong><u>كيفية استخدام ميران</u></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء <strong>ميران</strong> عن طريق الحقن أو التسريب في أحد الأوردة الكبيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عادة ما يتم إعطاء <strong>ميران</strong> بواسطة الطبيب أو الممرض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم خلط أو إضافة حقن <strong>ميران</strong> إلى أية محاليل تحتوي على أدوية أخرى (انظر أدناه عدم التوافق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قد تستغرق مدة الحقن خمس دقائق أو ما بين 15- 30 دقيقة. قد يخبرك طبيبك المعالج حول كيفية إعطاء ميران</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; عادة يجب أخذ الحقن في نفس المواعيد كل يوم.&nbsp;</p><p dir="RTL"><strong>إذا استعملت</strong> <strong>على سبيل الخطأ ميران بجرعة أكبر من الاعتيادية </strong></p><p dir="RTL">إذا استعملت على سبيل الخطأ جرعة أكبر من الجرعة الموصوفة لك، يرجى منك التواصل مع طبيبك المعالج أو أقرب مستشفى لديك على الفور.</p><p dir="RTL"><strong>إذا سهوت عن استخدام ميران</strong></p><p dir="RTL">إذا سهوت عن استخدام أحد حقن <strong>ميران</strong>، فيجب عليك أخذها في أسرع وقت ممكن حال تذكرها، ولكن إذا كان موعد الجرعة التالية قد اقترب، فيستحسن الاستمرار في جدول الجرعات دون أخذ الجرعة التي قد سهوت عنها. لا تأخذ جرعة مضاعفة (جرعتين في آن واحد) لتعويض الجرعات المفردة التي قد سهوت عن أخذها.</p><p dir="RTL"><strong>إذا توقفت عن استخدام ميران&nbsp;&nbsp; </strong></p><p dir="RTL">لا تتوقف عن استخدام<strong> ميران</strong> من تلقاء نفسك حتى يخبرك الطبيب المعالج بذلك.</p><p dir="RTL"><strong>في حال كان لديك أية استفسارات أخرى تخص استعمال هذا الدواء، يرجى منك استشارة طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يتسبب هذا الدواء في حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>تفاعلات تحسُسية خطيرة:</strong></p><p dir="RTL">في حال عانيت من حدوث أحد هذه العلامات و الأعراض<strong>، يجب عليك إخبار طبيبك المعالج أو الممرض على الفور. </strong>فقد تكون بحاجة إلى الخضوع للعناية الطبية العاجلة<strong>. </strong>قد تشتمل هذه الأعراض على ظهور مفاجئ لكل مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; طفح شديد، حكة أو شرى على الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، الشفتين، اللسان أو أجزاء أخرى من الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، أزيز أو اضطراب في التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة&nbsp; والتي تتضمن ما يلي:</p><p dir="RTL">&bull;&nbsp; تتضمن تفاعلات فرط الحساسية الخطيرة على الحمى، الطفح الجلدي وتغيرات في اختبارات الدم التي تتحقق من كفاءة عمل آلية الكبد (ارتفاع مستوى إنزيمات الكبد) وارتفاع تعداد أحد أنواع خلايا الدم البيضاء (الحمضات) وتضخم الغدد الليمفاوية. قد تكون هذه العلامات دلالة على حدوث اضطرابات الحساسية التي تصيب أعضاء متعددة من الجسم.</p><p dir="RTL">&bull;&nbsp; طفح جلدي أحمر مصحوب بقشور، نتوءات جلدية تحتوي على صديد، بثور أو تقشر في الجلد، والتي قد يصاحبها ارتفاع في درجة الحرارة وآلام في المفاصل.</p><p dir="RTL">&bull;&nbsp; طفح جلدي حاد والذي قد يظهر على هيئة بقع دائرية حمراء اللون مع ظهور بثور مركزية على الجذع ، تقشر الجلد، تقرحات الفم، الحلق، الأنف، الأعضاء التناسلية والعين ويمكن أن يسبقهما حدوث حمى وأعراض تشبه أعراض الأنفلونزا (متلازمة ستيفنز جونسون) أو قد تتخذ شكل أكثر حدة (تنخر البشرة السمي).</p><p dir="RTL"><strong>تلف خلايا الدم الحمراء (غير معروفة)، تشمل العلامات ما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مواجهة صعوبة في التنفس في الأحوال العادية بشكل غير متوقع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول إلى الأحمر أو البني.</p><p dir="RTL">في حال لاحظت أياً من المذكور أعلاه، <strong>يرجى منك التواصل مع طبيبك المعالج على الفور.</strong></p><p dir="RTL"><strong>تأثيرات جانبية أخرى محتملة:</strong></p><p dir="RTL"><strong>شائعة (قد تصيب شخص واحد لكل 10 من الأشخاص).</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن (المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الإعياء (قيء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة في الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; شعور بالألم والالتهاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; زيادة تعداد الصفيحات في الدم (كما يظهر في فحص الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات الدم، بما في ذلك الفحوصات التي يتم إجراؤها لتقييم مدى كفاءة وظائف الكبد.</p><p dir="RTL"><strong>غير شائعة (قد تصيب شخص واحد لكل 100 من الأشخاص).</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الدم. بما في ذلك نقص تعداد الصفيحات الدموية (مما قد يجعلك عرضة لحدوث الكدمات بصورة أسهل)، زيادة تعداد بعض خلايا الدم البيضاء وانخفاض تعداد خلايا الدم البيضاء الأخرى وزيادة كميات المادة المعروفة باسم البيليروبين. قد يجري لك الطبيب المعالج فحوصات الدم بين كل فترة وأخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات الدم، بما في ذلك الفحوصات التي يتم إجراؤها لتقييم مدى كفاءة الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالوخز (يشبه الوخز بالدبابيس والإبر).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تصيب الفم أو العدوى المهبلية التي تسببها الفطريات (مرض القلاع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الأمعاء يصاحبه إسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة في المكان الذي يحقن فيه <strong>ميران</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تغيرات أخرى في الدم. تشتمل أعراضها على الإصابة بعدوى متكررة الحدوث، ارتفاع حرارة الجسم والتهاب الحلق. قد يجري لك الطبيب فحوصات للدم بين كل فترة وأخرى.</p><p dir="RTL"><strong>نادرة (قد تصيب شخص واحد لكل 1000 من الأشخاص).</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; نوبة من التشنجات.</p><p dir="RTL">ارتباك وتوهان حاد (الهذيان).</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة.<strong> </strong>كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم الفاكس:&nbsp; </strong>&nbsp;7662-205-11-966+</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على:</strong> 2038222-11-966+</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وصلة هاتف:</strong>2340-2356-2317</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الخط الساخن: </strong>19999</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني:</strong><strong> </strong><strong>&nbsp;</strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: </strong>www.sfda.gov.sa/npc</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول المجلس التعاون الخليجي الأخرى: </strong>يرجى الاتصال بالجهات المختصة ذات الصلة</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>لا تستخدم <strong>ميران</strong> بعد انتهاء تاريخ الصلاحية المذكور على العلبة وملصق الزجاجة، يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>لا تستخدم <strong>ميران</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong>يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL"><strong>-&nbsp;&nbsp; </strong><strong>قبل التحضير، يحفظ في درجة حرارة أقل من 30 &ordm;م.</strong></p><p dir="RTL"><strong>الاستقرار بعد التحضير:</strong></p><p dir="RTL"><strong><u>الحقن دفعة واحدة في الوريد</u></strong><strong><u>:</u></strong><strong><u> </u></strong></p><p dir="RTL">يتم تحضير محلول <strong>ميران</strong> للحقن دفعة واحدة في الوريد بإضافة الماء المعد للحقن حتى الوصول إلى التركيز النهائي 50 ملغم/ملليلتر.</p><p dir="RTL">تبين أن الاستقرار الكيميائي والفيزيائي للمحاليل المحضرة للحقن دفعة واحدة في الوريد&nbsp; هو 3 ساعات إذا تم حفظها في درجة حرارة تصل إلى &ordm;25م أو 12 ساعة إذا تم حفظها في الثلاجة (درجة حرارة 2- &ordm;8م).</p><p dir="RTL">وفقاً للناحية الميكروبيولوجية، يجب استخدام المنتج على الفور، .إلا إذا كانت طريقة الفتح / التحضير / التخفيف تحول دون التعرض لخطر التلوث الميكروبيولوجي.</p><p dir="RTL">إذا لم يتم استخدامه على الفور فإن شروط التخزين بعد التحضير والتخفيف هي مسؤولية المستخدم.</p><p dir="RTL"><strong><u>الحقن عن طريق التسريب في الوريد</u></strong><strong><u>:</u></strong></p><p dir="RTL">يتم تحضير محلول <strong>ميران</strong> المعد للتسريب في الوريد بإضافة كلوريد الصوديوم 0.9٪ المعد للتسريب أو بإضافة محلول الدكستروز 5٪ حتى يصل التركيز النهائي من 1 إلى 20 ملغم/ملليلتر.</p><p dir="RTL">تبين أن الاستقرار الكيميائي والفيزيائي للمحاليل المعدة للتسريب في الوريد باستخدام كلوريد الصوديوم 0.9٪ هو 3 ساعات إذا تم حفظها في درجة حرارة تصل إلى &ordm;25م أو 24 ساعة إذا تم حفظها في الثلاجة (درجة حرارة 2- &ordm;8م).</p><p dir="RTL">وفقاً للناحية الميكروبيولوجية، يجب استخدام المنتج على الفور، إلا إذا كانت طريقة الفتح / التحضير / التخفيف تحول دون التعرض لخطر التلوث الميكروبيولوجي.</p><p dir="RTL">إذا لم يتم استخدامه على الفور فإن شروط التخزين بعد التحضير والتخفيف هي مسؤولية المستخدم.</p><p dir="RTL">يجب استخدام المحاليل المحضرة باستخدام محلول الدكستروز 5٪ على الفور.</p><p dir="RTL">يجب عدم تجميد المحاليل المحضرة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ميروبينيم.</p><p>تحتوي كل زجاجة على: ثلاثي هيدرات الميروبينيم المعقم بما يكافئ 0.5 غرام&nbsp; أو1 غرام &nbsp;من ميروبينيم.</p><p>المواد الأخرى: كربونات الصوديوم المعقم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر ميران 0.5 غرام أو ميران 1 ملغم في عبوات تحتوي على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
01/10/2020

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Miran 0.5g powder for solution for I.V. Injection or Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item no.	 Material Name	Scale (mg/vial)
		
	Active Ingredient:	
1.		*Sterile Meropenem Trihydrate 	570.000 *
	  Equivalent to Meropenem	500.000
		
	Inactive Ingredients:	
1.		Sterile Sodium carbonate	104.000










* Quantity of sterile Meropenem Trihydrate may vary from batch to batch according to the potency of raw material.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile powder for solution for I.V. Injection or Infusion
Description: Glass vial containing white to light yellow powder

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Miran</strong> is indicated for the treatment of the following infections in adults and children aged 3 months and older (see sections 4.4 and 5.1):</p><p>&sect; Severe pneumonia, including hospital and ventilator-associated pneumonia.</p><p>&sect; Broncho-pulmonary infections in cystic fibrosis</p><p>&sect; Complicated urinary tract infections</p><p>&sect; Complicated intra-abdominal infections</p><p>&sect; Intra- and post-partum infections</p><p>&sect; Complicated skin and soft tissue infections</p><p>&sect; Acute bacterial meningitis</p><p><strong>Miran</strong> may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The tables below provide general recommendations for dosing.</p><p>The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.</p><p>A dose of up to 2 g three times daily in adults and adolescents and a dose of up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g.&nbsp;<em>Enterobacteriaceae</em>,&nbsp;<em>Pseudomonas aeruginosa,</em>&nbsp;<em>Acinetobacter&nbsp;</em>spp.), or very severe infections.</p><p>Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).</p><p><strong><u>Adults and Adolescents</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:530px"><tbody><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered every </strong></p><p><strong>8 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia.</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Intra- and post-partum infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>1 g</p></td></tr></tbody></table><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6).</p><p>Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.</p><p><strong><u>Renal impairment</u></strong></p><p>The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.</p><table border="1" cellspacing="0" cellpadding="0" style="width:530px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p>(based on &ldquo;unit&rdquo; dose range of 500 mg or 1 g or 2 g, see table above)</p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>26-50</p></td><td style="vertical-align:top"><p>one unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>10-25</p></td><td style="vertical-align:top"><p>half of one unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10</p></td><td style="vertical-align:top"><p>half of one unit dose</p></td><td style="vertical-align:top"><p>every 24 hours</p></td></tr></tbody></table><p>Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.</p><p>There are no established dose recommendations for patients receiving peritoneal dialysis.</p><p><strong><u>Hepatic impairment</u></strong></p><p>No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).</p><p><strong><u>Dose in elderly patients</u></strong></p><p>No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.</p><p><strong>Paediatric population</strong></p><p><u>Children under 3 months of age</u></p><p>The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).</p><p><u>Children from 3 months to 11 years of age and up to 50 kg body weight</u></p><p>The recommended dose regimens are shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:529px"><tbody><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered every 8 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>20 mg/kg</p></td></tr></tbody></table><p><u>Children over 50 kg body weight</u></p><p>The adult dose should be administered.</p><p>There is no experience in children with renal impairment.</p><p><strong><u>Method of administration</u></strong></p><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	Hypersensitivity to any other carbapenem antibacterial agent.
	Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.</p><p><strong><em><u>Enterobacteriaceae</u></em></strong><strong><u>,&nbsp;<em>Pseudomonas aeruginosa</em>&nbsp;and&nbsp;<em>Acinetobacter</em>&nbsp;spp. resistance</u></strong></p><p>Resistance to penems of&nbsp;<em>Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter</em>&nbsp;spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.</p><p><strong><u>Hypersensitivity reactions</u></strong></p><p>As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).</p><p>Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.</p><p>If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken.</p><p>Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.</p><p><strong><u>Antibiotic-associated colitis</u></strong></p><p>Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for&nbsp;<em>Clostridium difficile</em>&nbsp;should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><strong><u>Seizures</u></strong></p><p>Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).</p><p><strong><u>Hepatic function monitoring</u></strong></p><p>Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).</p><p>Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).</p><p><strong><u>Direct antiglobulin test (Coombs test) seroconversion</u></strong></p><p>A positive direct or indirect Coombs test may develop during treatment with meropenem.</p><p><strong><u>Concomitant use with valproic acid/sodium valproate/valpromide</u></strong></p><p>The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).</p><p><strong>Miran contains sodium.</strong></p><p>This medicinal product contains sodium, which should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific medicinal product interaction studies other than probenecid were conducted.</p><p>Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.</p><p>The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.</p><p>Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).</p><p><strong><u>Oral anti-coagulants</u></strong></p><p>Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.</p><p><strong><u>Paediatric population</u></strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are no or limited amount of data from the use of meropenem in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.</p><p><strong><u>Breast-feeding</u></strong></p><p>Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3 %), rash (1.4 %), nausea/vomiting (1.4 %) and injection site inflammation (1.1 %). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5-4.3 %).</p><p><strong><u>Tabulated risk of adverse reactions</u></strong></p><p>In the table below all adverse reactions are listed by system organ class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:529px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Event</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>oral and vaginal candidiasis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>thrombocythaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>agranulocytosis, haemolytic anaemia, thrombocytopenia, neutropenia, leukopenia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>anaphylaxis (see sections 4.3 and 4.4), angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>delirium</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>paraesthesiae</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>convulsions (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain, vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>antibiotic-associated colitis (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section 4.4), urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms, acute generalised exanthematous pustulosis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased, blood urea increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>inflammation, pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombophlebitis, pain at the injection site</p></td></tr></tbody></table><p><strong><u>Paediatric population</u></strong></p><p>Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.</p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at </strong>+966-11-2038222, Exts: 2317-2356-2340</p><p><strong>Reporting Hotline: </strong>19999</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p><p>&sect; <strong>Other GCC States: </strong>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.</p><p>In individuals with normal renal function, rapid renal elimination will occur.</p><p>Haemodialysis will remove meropenem and its metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> antibacterials for systemic use, carbapenems</p><p>ATC code: J01DH02</p><p><strong><u>Mechanism of action</u></strong></p><p>Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).</p><p><strong><u>Pharmacokinetic/Pharmacodynamic (PK/PD) relationship</u></strong></p><p>Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T&gt;MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40 % of the dosing interval. This target has not been established clinically.</p><p><strong><u>Mechanism of resistance</u></strong></p><p>Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of beta-lactamases that can hydrolyse carbapenems.</p><p>Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the European Union.</p><p>There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterial agents when the mechanism involved include impermeability and/or an efflux pump(s).</p><p><strong><u>Breakpoints</u></strong></p><p>European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing are presented below.</p><p><strong>EUCAST clinical MIC breakpoints for meropenem (2013-02-11, v 3.1)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:530px"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible (S)</strong></p><p><strong>(mg/l)</strong></p></td><td style="vertical-align:top"><p><strong>Resistant (R)</strong></p><p><strong>(mg/l)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus groups&nbsp;</em>A, B, C and G</p></td><td style="vertical-align:top"><p>note 6</p></td><td style="vertical-align:top"><p>note 6</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae<sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Viridans&nbsp;</em>group<em>&nbsp;streptococci<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>note 3</p></td><td style="vertical-align:top"><p>note 3</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae<sup>1, 2</sup>&nbsp;and Moraxella catarrhalis<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis<sup>2,4</sup></em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive anaerobes except&nbsp;<em>Clostridium difficile</em></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative anaerobes</p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Listeria monocytogenes</em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>5</sup></p></td><td style="vertical-align:top"><p>&le; 2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Meropenem breakpoints for&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;and&nbsp;<em>Haemophilus influenzae</em>&nbsp;in meningitis are 0.25 mg/l (Susceptible) and 1 mg/l (Resistant).</p><p><sup>2</sup>&nbsp;Isolates with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC values above the current resistant breakpoint they should be reported resistant.</p><p><sup>3</sup>&nbsp;Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.</p><p><sup>4</sup>&nbsp;Breakpoints relate to meningitis only.</p><p><sup>5</sup>&nbsp;Non-species related breakpoints have been determined using PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints. Non species related breakpoints are based on the following dosages: EUCAST breakpoints apply to meropenem 1000 mg x 3 daily administered intravenously over 30 minutes as the lowest dose. 2 g x 3 daily was taken into consideration for severe infections and in setting the I/R breakpoint.</p><p><sup>6</sup> The beta-lactam susceptibility of streptococcus groups A, B, C and G is inferred from the penicillin susceptibility.</p><p>-- = Susceptibility testing not recommended as the species is a poor target for therapy with the drug. Isolates may be reported as R without prior testing.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.</p><p><strong>Commonly susceptible species</strong></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecalis</em><sup>$</sup></p><p><em>Staphylococcus aureus (</em>methicillin-susceptible<em>)</em><sup>&pound;</sup></p><p><em>Staphylococcus&nbsp;</em>species (methicillin-susceptible) including&nbsp;<em>Staphylococcus epidermidis</em></p><p><em>Streptococcus agalactiae</em>&nbsp;(Group B)</p><p><em>Streptococcus milleri</em>&nbsp;group (<em>S. anginosus</em>,&nbsp;<em>S. constellatus</em>, and&nbsp;<em>S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus pyogenes</em>&nbsp;(Group A)</p><p><u>Gram-negative aerobes</u></p><p><em>Citrobacter freundii</em></p><p><em>Citrobacter koseri</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Morganella morganii</em></p><p><em>Neisseria meningitides</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia marcescens</em></p><p><u>Gram-positive anaerobes</u></p><p><em>Clostridium perfringens</em></p><p><em>Peptoniphilus asaccharolyticus</em></p><p><em>Peptostreptococcus</em>&nbsp;species (including&nbsp;<em>P. micros, P anaerobius, P. magnus</em>)</p><p><u>Gram-negative anaerobes</u></p><p><em>Bacteroides caccae</em></p><p><em>Bacteroides fragilis</em>&nbsp;group</p><p><em>Prevotella bivia</em></p><p><em>Prevotella disiens</em></p><p><strong>Species for which acquired resistance may be a problem</strong></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecium</em><sup>$&dagger;</sup></p><p><u>Gram-negative aerobes</u></p><p><em>Acinetobacter&nbsp;</em>species</p><p><em>Burkholderia cepacia</em></p><p><em>Pseudomonas aeruginosa</em></p><p><strong>Inherently resistant organisms</strong></p><p><u>Gram-negative aerobes</u></p><p><em>Stenotrophomonas maltophilia</em></p><p><em>Legionella&nbsp;</em>species</p><p><strong>Other micro-organisms</strong></p><p><em>Chlamydophila pneumoniae</em></p><p><em>Chlamydophila psittaci</em></p><p><em>Coxiella burnetii</em></p><p><em>Mycoplasma pneumoniae</em></p><p><sup>$</sup>&nbsp;Species that show natural intermediate susceptibility</p><p><sup>&pound;</sup>&nbsp;All methicillin-resistant staphylococci are resistant to meropenem</p><p><sup>&dagger;</sup>&nbsp;Resistance rate &ge; 50% in one or more EU countries.</p><p>Glanders and melioidosis: Use of meropenem in humans is based on<em>&nbsp;in vitro B.mallei&nbsp;</em>and&nbsp;<em>B. pseudomallei&nbsp;</em>susceptibility data and on limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of glanders and melioidosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects the mean plasma half-life is approximately 1 hour; the mean volume of distribution is approximately 0.25 l/kg (11-27 l) and the mean clearance is 287 ml/min at 250 mg falling to 205 ml/min at 2 g. Doses of 500, 1000 and 2000 mg doses infused over 30 minutes give mean Cmax values of approximately 23, 49 and 115 &mu;g/ml respectively, corresponding AUC values were 39.3, 62.3 and 153 &mu;g.h/ml. After infusion over 5 minutes Cmax values are 52 and 112 &mu;g/ml after 500 and 1000 mg doses respectively. When multiple doses are administered 8-hourly to subjects with normal renal function, accumulation of meropenem does not occur.</p><p>A study of 12 patients administered meropenem 1000 mg 8 hourly post-surgically for intra-abdominal infections showed a comparable Cmax and half-life to normal subjects but a greater volume of distribution 27 l.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Distribution</u></strong></p><p>The average plasma protein binding of meropenem was approximately 2 % and was independent of concentration. After rapid administration (5 minutes or less) the pharmacokinetics are biexponential but this is much less evident after 30 minutes infusion. Meropenem has been shown to penetrate well into several body fluids and tissues: including lung, bronchial secretions, bile, cerebrospinal fluid, gynaecological tissues, skin, fascia, muscle, and peritoneal exudates.</p><p><strong><u>Biotransformation</u></strong></p><p>Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. In vitro meropenem shows reduced susceptibility to hydrolysis by human dehydropeptidase-I (DHP-I) compared to imipenem and there is no requirement to co-administer a DHP-I inhibitor.</p><p><strong><u>Elimination</u></strong></p><p>Meropenem is primarily excreted unchanged by the kidneys; approximately 70 % &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(50 &ndash;75 %) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Faecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.</p><p><strong><u>Renal insufficiency</u></strong></p><p>Renal impairment results in higher plasma AUC and longer half-life for meropenem. There were AUC increases of 2.4 fold in patients with moderate impairment (CrCL 33-74 ml/min), 5 fold in severe impairment (CrCL 4-23 ml/min) and 10 fold in haemodialysis patients (CrCL &lt;2 ml/min) when compared to healthy subjects (CrCL &gt;80 ml/min). The AUC of the microbiologically inactive ring opened metabolite was also considerably increased in patients with renal impairment. Dose adjustment is recommended for patients with moderate and severe renal impairment (see section 4.2).</p><p>Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.</p><p><strong><u>Hepatic insufficiency</u></strong></p><p>A study in patients with alcoholic cirrhosis shows no effect of liver disease on the pharmacokinetics of meropenem after repeated doses.</p><p><strong><u>Adult patients</u></strong></p><p>Pharmacokinetic studies performed in patients have not shown significant pharmacokinetic differences versus healthy subjects with equivalent renal function. A population model developed from data in 79 patients with intra-abdominal infection or pneumonia, showed a dependence of the central volume on weight and the clearance on creatinine clearance and age.</p><p><strong><u>Paediatric population</u></strong></p><p>The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg showed Cmax values approximating to those in adults following 500, 1000 and 2000 mg doses, respectively. Comparison showed consistent pharmacokinetics between the doses and half-lives similar to those observed in adults in all but the youngest subjects (&lt;6 months t1/2 1.6 hours). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60 % of the dose is excreted in urine over 12 hours as meropenem with a further 12 % as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20 % of concurrent plasma levels although there is significant inter-individual variability.</p><p>The pharmacokinetics of meropenem in neonates requiring anti-infective treatment showed greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 hours. Monte Carlo simulation based on a population PK model showed that a dose regimen of 20 mg/kg 8 hourly achieved 60 %T&gt;MIC for&nbsp;<em>P. aeruginosa</em>&nbsp;in 95 % of pre-term and 91 % of full term neonates.</p><p><strong><u>Elderly</u></strong></p><p>Pharmacokinetic studies in healthy elderly subjects (65-80 years) have shown a reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, and a smaller reduction in non-renal clearance. No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies indicate that meropenem is well tolerated by the kidney. Histological evidence of renal tubular damage was seen in mice and dogs only at doses of 2000 mg/kg and above after a single administration and above and in monkeys at 500 mg/kg in a 7-day study.</p><p>Meropenem is generally well tolerated by the central nervous system. Effects were seen in acute toxicity studies in rodent at doses exceeding 1000 mg/kg.</p><p>The IV LD<sub>50</sub>&nbsp;of meropenem in rodents is greater than 2000 mg/kg.</p><p>In repeat dose studies of up to 6 months duration only minor effects were seen including a decrease in red cell parameters in dogs.</p><p>There was no evidence of mutagenic potential in a conventional test battery and no evidence of reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.</p><p>There was no evidence of increased sensitivity to meropenem in juveniles compared to adult animals. The intravenous formulation was well tolerated in animal studies.</p><p>The sole metabolite of meropenem had a similar profile of toxicity in animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Inactive Ingredients:</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterile sodium carbonate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months from the date of manufacturing
Intravenous bolus injection administration
A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/mL. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C).
From a microbiological point of view, unless the method of opening/ reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
If not used immediately in-use storage times and conditions are the responsibility of the user.
Intravenous infusion administration
A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C or 24 hours under refrigerated conditions (2-8°C).
From a microbiological point of view, unless the method of opening/ reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
If not used immediately in-use storage times and conditions are the responsibility of the user.
Reconstituted solution of the product in 5% dextrose solution should be used immediately.
The constituted solutions should not be frozen.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Before reconstitution:</strong> Store below 30&deg;C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>USP Type-III glass vial with a printed label, 1 vial packed in a printed box along with a leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Injection</u></strong></p><p>Meropenem to be used for bolus intravenous injection should be constituted with sterile water for injection.</p><p><strong><u>Infusion</u></strong></p><p>For intravenous infusion meropenem vials may be directly constituted with 0.9% sodium chloride or 5% dextrose solutions for infusion.</p><p>Each vial is for single use only.</p><p>Standard aseptic techniques should be used for solution preparation and administration.</p><p>The solution should be shaken before use.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01. October. 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>